Inve India ▾

Jubilant Pharmova share price & results

Jubilant Pharmova Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Global pharma firm spanning radiopharma, allergy immunotherapy, sterile-injectable CDMO, CRDMO and generics.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue67.1 ₹ crore+12.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin17.9 %+0.6 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit7.3 ₹ crore+25.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity5.81 %−0.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-1.45 %−0.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)16.25 %+6.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 4 judged targets kept · 11 open · verdicts reflect calls analysed to Q4 FY26.

Jubilant Pharmova Limited management guidance track record on Inve: 15 targets tracked across analysed earnings calls (3 achieved, 1 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Radiopharmacy BreakevenBreakeven in FY24Q1 FY23Q4 FY26:This past promise was not discussed.
Call transcript, Q4 FY26 · 22 May 2026		Achieved
EBITDA Margin23-25% by FY30
Call transcript, Q3 FY25 · 24 Feb 2025		Q3 FY25Q4 FY26:FY26 EBITDA margin was 15.9%, down 99 bps YoY. While H2 FY27 guidance is for 17-18%, the current level and negative trend are significantly below the trajectory needed to reach 23-25% by FY30.
Call transcript, Q4 FY26 · 22 May 2026		At Risk
Total Revenue₹13,500 crores by FY30
Call transcript, Q3 FY25 · 24 Feb 2025		Q3 FY25Q4 FY26:FY26 revenue reported at ₹8,280 Cr, a 14% YoY growth. This trajectory is consistent with the long-term goal, which requires a ~13% CAGR from this base.
Call transcript, Q4 FY26 · 22 May 2026		On Track

Source: Inve Guidance Tracker for Jubilant Pharmova Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Jubilant Pharmova Limited's 15 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 12 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹959.8 +2.43% · +₹22.8

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −14.2% 1Y

₹0.8k₹0.9k₹1.0k₹1.1k₹1.2kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q4 FY26 — 22 May 2026

1Y: ₹1,118.6 on 24 Oct 2025 → ₹959.8. High ₹1,181.2 (4 Nov 2025), low ₹807.65 (11 Mar 2026).

Previous close
₹937
Market cap
₹14.9k Cr
52-week range
₹807.65 – ₹1,181.2
One year
−14.62%
Price to earnings (TTM to Jun 2026)
38.47×
Return on equity (TTM to Jun 2026)
5.81%

Overview

Symbol
NSE:JUBLPHARMA
Exchange
NSE
Currency
INR

What Jubilant Pharmova Limited does

Based on the company's own presentations, annual report and earnings calls.

Jubilant Pharmova is an integrated global pharmaceutical company operating six businesses: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (drug discovery and API), Generics, and Proprietary Novel Drugs. It manufactures and distributes radiopharmaceutical diagnostic and therapeutic products through its own US radiopharmacy network, makes allergenic extracts and venom immunotherapy products for the US and other markets, and runs contract manufacturing and drug-discovery operations serving global pharmaceutical and biotech customers. Its Generics arm develops and distributes solid dosage formulations into regulated markets, while its novel-drugs unit is developing precision oncology and auto-immune therapies.

Segments

  • Radiopharma
  • Allergy Immunotherapy
  • CDMO Sterile Injectables
  • CRDMO
  • Generics
  • Proprietary Novel Drugs
US radiopharmacy network
45 radiopharmacies — 2nd-largest network in the US
PET manufacturing facilities
3 operational facilities
CDMO sterile-injectables plants
Spokane, Washington (US) and Montreal, Canada
CRDMO research centres
3 world-class research centres — 2 in India, 1 in France
API manufacturing facility
Nanjangud, Karnataka, India (US FDA-approved)
Generics manufacturing facility
Roorkee, Uttarakhand, India
Founded 1978Headquarters Bhartiagram, Gajraula, Amroha, Uttar Pradesh, IndiaEmployees 5,500 (FY26 (Mar-2026)) Company website

How the price took the results

close before → close after

Q4 FY26
−0.5%
22 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Jubilant Pharmova Limited

Free account: one company. Everything above stays public.

Write why you follow Jubilant Pharmova Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Jubilant Pharmova Limited

Guides on how to read this kind of business and the numbers that matter.